Program Book

Recommendations

Info

2253 UM1 PRELIMINARY STUDY OF VASCULAR FLOW IN CHOR- OIDAL TUMORS AND PSEUDOTUMORS C.M. Gentile, M. Faria Dovasio , Lucila Tajtelbaum, Atilio Lombardi , J. Oscar Croxatto (carolina.gentile@gmail.com) Hospital Italiano de Buenos Aires, Argentina Purpose. The aim of this study was to describe and analyze the hemodynamic findings pre and post treatment in choroidal melanocytic tumors and in pseudotumors using high resolution doppler color and spectral ultrasound. Methods. Twenty six patients (aged ranged from 38 and 86 years- old) with presumed diagnosis of choroidal tumour or pseudotumors were included. The B-Scan and Doppler ultrasound images were obtained with ESAOTE My Lab 70 vision, Italia equipment. Intralesional vascularization and spectral doppler analysis from intratumoral vascular region and from tumoral base was performed using values of flow velocity in systole and diastole, and resistive index (systolic-diastolic/systolic, RI). Results. Vascular flow with low resistive index was observed in patients with untreated choroidal melanoma. After therapy, the intratumoral vascularization decreased and increased the RI. In three patients with treated melanomas, intratumoral vascularization in association with tumoral growing was observed. There was no tumoral vascularization in patients with choroidal nevus except for the base (choroid). Doppler ultrasound in patients with media opacity and presumed diagnosis of choroidal haematoma versus melanoma, revealed absence of intralesional vascularization and it showed presence of vascularization only on its base (choroidal vessels). Conclusions. Doppler color and spectral ultrasound is a non invasive and useful clinical technique which may be used in differential diagnosis between choroidal haematoma and advanced melanoma in patients with media opacity. It could be used as an additional tool for the differential diagnosis of choroidal nevus and melanoma and for evaluation of effectiveness in patients with choroidal melanoma after conservative therapy. Financial disclosure. None 622 UM2 AUSTRALIA AND NEW ZEALAND STUDY OF PDT IN CHOROIDAL AMELANOTIC MELANOMA (ANZSOPI- CAM) - TWO YEAR RESULTS William Glasson, William G. Campbell, Sid Finnigan, Michael Giblin, Peter Hadden, Timothy Isaacs, John D. McKenzie, James Muecke, Tanya M. Pejnovic. (glasson@terraceeyecentre.com.au) Dr William G. Campbell is the principal investigator, other authors are co-investigators. Purpose. ANZSOPICAM is an investigator-initiated prospective multicentre clinical trial of photodynamic therapy in choroidal amelanotic melanoma. This paper summarises the first two years’’ results. Methods. Patients presenting with posteriorly-located amelanotic melanoma were recruited into the study. After full ocular and systemic assessment photodynamic therapy was applied with the Zeiss Visulas laser, using verteporfin as the photosensitiser. PDT was repeated at UVEAL MELANOMA Abstracts 96 three monthly intervals intil the melanoma had completely regressed. Results. 31 patients were recruited in the first two years. Complete regression of the melanoma has been achieved in 19 patients to date; eight after just one treatment, five following two treatments, five required three sessions of PDT, whilst in one patient four treatments were necessary. The tumour in the remaining 12 patients demonstrated a response to PDT; of these 10 are still undergoing treatment, one was lost to follow-up and one, an 85 year old male, died of an unrelated condition three months after his initial PDT. Vision has remained stable or improved in all but three patients. Three participants developed small, local recurrences that responded favourably to a further session of PDT. So far no evidence of systemic metastatic disease has been found in any patients. Conclusions. The results of this study to date indicate PDT is effective in causing regression of amelanotic melanoma, in the majority of cases without compromising vision. The study is ongoing. Financial disclosure. None 1618 UM3 PHOTODYNAMIC THERAPY AS ADJUVANT TREAT- MENT FOR AMELANOTIC CHOROIDAL MELANOMA DEBULKING Maria A. Blasi, Monica M. Pagliara, Andrea Scupola, Carmela G. Caputo, Emilio Balestrazzi (mariaantonietta.blasi@rm.unicatt.it) Department of Ophthalmology, Catholic University, Rome, Italy Purpose. To evaluate the efficacy of photodynamic therapy (PDT) as adjuvant treatment to reduce tumour thickness before brachytherapy for amelanotic choroidal melanoma. Methods. Patients and Methods: Fourteen patients with amelanotic choroidal melanoma were recruited. Inclusion criterion was diagnosis of amelanotic choroidal melanoma based on ophthalmoscopy, ultrasonography (US), fluorescein angiography (FA), and ICGA. All patients underwent PDT treatment using verteporfin infused intravenously at a dose of 6mg/m2body surface area. Five minutes after infusion, a 689nm laser was applied with a light dose of 100 J/cm 2 at an irradiance of 600mW/cm2 over an interval of 166 seconds. One month after PDT all patients underwent brachytherapy. Results. One month after PDT treatment US showed reduction of tumour height in 9 patients (64.28%) (Group A), stable thickness in 3 patients ( 21.42%) (Group B) and minimal increase in thickness in 2 patients (14.28%) (Group C). The mean tumour thickness was 5.39mm at baseline, with a mean reduction of 25.33% in Group A; 4.60mm and no reduction in Group B; 2.63mm with a mean increase of 6.08% in Group C. In Group A, the mean dose of irradiation to macula and optic nerve calculated at baseline was 76.61 and 54.2 Gy, after PDT it was 43.44 and 35.05 Gy, with a decrease of 43.3% and 35.3% respectively. Conclusions. The goal of treatment for uveal melanoma is to achieve local tumour control while minimizing damage to macula and optic nerve. Use of PDT as adjuvant therapy in order to reduce tumour thickness and consequently brachytherapy toxic effects is encouraging. Financial disclosure. None 1413 UM4 MACROPHAGE INFILTRATION IN PREVIOUSLY-IRRA- DIATED UVEAL MELANOMA M.J. Jager, THK Vu, IHG Bronkhorst, M Versluis, M Marinkovic, SG van Duinen, GPM Luyten (m.j.jager@lumc.nl)
Departments of Ophthalmology and Pathology, Leiden University Medical Center (LUMC), The Netherlands. Purpose. Previous studies at our department showed that uveal melanoma with a bad prognosis contained high numbers of infiltrating macrophages, especially of the M2 phenotype. We wondered whether prior treatment with irradiation would affect the degree of inflammation as displayed by the number of tumor-infiltrating macrophages and lymphocytes. Methods. We analyzed 46 eyes containing a uveal melanoma that were previously treated with radioactive plaque or proton beam therapy, and where the eye had to be enucleated due to tumor recurrence, nonresponsiveness, or complications after irradiation. Immunofluorescence staining was performed to determine the presence of CD68+ and CD68+CD163+macrophages, CD3+, CD8+ and Foxp3+ regulatory T lymphocytes. Outcomes were compared with known clinical and histological prognostic parameters. Results. Numbers of CD68+ and CD68+CD163+ macrophages in secondarily-enucleated eyes varied widely, but were not related to the reason for enucleation. When compared to primarily-enucleated eyes, the lymphocytic infiltration was significantly (p
Page 1 and 2:
XV th NH City Hotel and Tower Boliv
Page 3 and 4:
List of Congress Meetings of the In
Page 5:
Table of Contents Welcome address K
Page 8 and 9:
Keynote Lectures Lymphoma of the oc
Page 10 and 11:
The venue for the Biannual Meeting
Page 12 and 13:
Buenos Aires Downtown MAP 12 Venue
Page 15 and 16:
MORNING 8.30-10.10 Papers (Moderato
Page 17 and 18:
50 RES 26 USING THE GLYCOLYTIC INHI
Page 19 and 20:
2226 RES 4 NOTCH SIGNALING PROMOTES
Page 21 and 22:
a reduction in the number of living
Page 23 and 24:
array further detected copy number
Page 25 and 26:
615 RES 21 TRB2 AND SKP2 IN THE RET
Page 27:
following treatment with 2-fluorode
Page 30 and 31:
1909 Rb14 RESULTS OF PATIENTS WITH
Page 32 and 33:
Posters Retinoblastoma 2006 RBp100
Page 34 and 35:
120 RBp135 MANAGEMENT OF AN ECTOPIC
Page 36 and 37:
After treatment, 10 patients lived
Page 38 and 39:
Methods. Six cycles of carboplatin
Page 40 and 41:
1940 RB15 PROTON THERAPY FOR RECURR
Page 42 and 43:
4. Fluoroscopy for cannula placemen
Page 44 and 45:
Methods. A retrospective chart revi
Page 46 and 47: Ruth A. Kleinerman1, Chu-ling Yu1,
Page 48 and 49: 2006 RBp100 RETINOBLASTOMA ASSESSME
Page 50 and 51: months. Mean delay between beginnin
Page 52 and 53: not associated with severity of RB.
Page 54 and 55: Conclusions. During a ten-year peri
Page 56 and 57: 30 RBp127 TREATMENT MODULATION IN R
Page 58 and 59: (follow-up 5 years). Two years afte
Page 61 and 62: 8.30-9.00 Poster presentations ECOp
Page 63 and 64: Uvea (Moderators: B. Damato, M. Sag
Page 65 and 66: Morning 8.30-9.00 Poster presentati
Page 67 and 68: 1621 EC1 EVALUATION OF THE “HEDGE
Page 69 and 70: Purpose. Ocular surface squamous ne
Page 71 and 72: (cargusale@yahoo.com) Oncology Serv
Page 73 and 74: of the tissues most commonly affect
Page 75 and 76: 2128 RF1 RETINOBLASTOMA David H. Ab
Page 77 and 78: Ocular Oncology Service, St Barthol
Page 79 and 80: Arturo Irarrazaval, Pablo Cazon, Os
Page 81 and 82: A CASE OF TEARING AND SWELLING OF T
Page 83 and 84: 1849 ECp101 FIVE CASES OF CARCINOMA
Page 85 and 86: patients. The isolated involvement
Page 87 and 88: exudative fluid from the hemangioma
Page 89: maximum of 7 rituximab injections.
Page 92 and 93: 153 UM14 PHENO-GENOTYPIC IDENTIFICA
Page 94 and 95: 8.30-9.00 Poster presentations UMp1
Page 98 and 99: Purpose. To determine the presence
Page 100 and 101: gene expression profile of melanocy
Page 102 and 103: the rarity of UM, timely completion
Page 104 and 105: C. Metz, T. Gkika, W. Sauerwein, N.
Page 106 and 107: Patients in the triamcinolone group
Page 108 and 109: 1350 Ump101 INDUCED EXPRESSION OF P
Page 110 and 111: Purpose. To report the Results of R
Page 112 and 113: 1547 Ump113 LONG-TERM OBSERVATIONS
Page 114 and 115: 2038 Ump119 VALUE OF DOPPLER ANALYS
Page 116: Methods. A total of 4070 patients w
Page 119: First authors Naseripour, Masood No
show all

Program Book

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?